Seeking Alpha
Seeking Alpha Portfolio App for iPad
Finance
(1)
Market Currents

Par Pharmaceutical (PRX +0.2%) says that its operating subsidiary has begun shipping 5 mg and 10...

  • Wednesday, January 2, 12:24 PM ET
    Par Pharmaceutical (PRX +0.2%) says that its operating subsidiary has begun shipping 5 mg and 10 mg strengths of rizatriptan benzoate tablets. Rizatriptan benzoate is indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years of age. Annual U.S. sales of the drug total approximately $653M.
Track new comments on this story

This news story has 1 comment:

  •  
    Rizatriptan is a generic drug of the "triptan" class, marketed by Merck as Maxalt. This is not the first generic triptan on the market (sumatriptan is), but it is a widely used and commonly effective treatment. Par is privately held.
    2 Jan, 12:46 PM Reply Like
LATEST|
TODAY SO FAR|
YESTERDAY
Other date
DJIA (DIA) S&P 500 (SPY)

HEALTHCARE ETFs IN FOCUS

Latest Healthcare Articles
More Latest Articles »